First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
Clinical trial NCT03665155 · COMPLETED
Trial details
- NCT number
- NCT03665155
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-05
- Primary completion
- 2020-04-20
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.